CYTO Live signals | Maximize Profits with Getagraph.com

SELL 122576 min ago

@ $1.986

Issued: 9 Feb 2024 @ 15:25

Return: -17.42%

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 16:00):

Stats
Today's Volume	30 000.00
Average Volume	1.21M
Market Cap	3.67M
EPS	$0 ( 2024-04-10 )
Next earnings date	( $0 ) 2024-05-16
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.100
ATR14	$0.0200 (1.22%)

Insider Trading

Date	Person	Action	Amount	type
2008-05-08	Carter Stephen	Sell	10 000	Common Stock
2008-05-08	Lokay Kevin G	Sell	185 439	Common Stock
2008-05-08	Lokay Kevin G	Sell	100 000	Options to Purchase Common Stock
2008-05-08	Mollica Joseph A	Sell	10 000	Common Stock
2007-11-13	Lokay Kevin G	Buy	500 000	Options to purchase Common Stock par value $0.01

INSIDER POWER
0.00
Last 33 transactions
Buy: 1 218 228 \| Sell: 315 439

Volume Correlation

Long: 0.00 (neutral)

Short: -0.33 (neutral)

Signal:(49.257) Neutral

Altamira Therapeutics Correlation

10 Most Positive Correlations
PIII	0.951
PROC	0.95
DISH	0.948
LGMK	0.945
AHCO	0.944
LGHL	0.942
EVLO	0.942
TTEC	0.941
MDRX	0.941
UPC	0.94

10 Most Negative Correlations
VKTX	-0.965
JMAC	-0.965
IQ	-0.96
DKDCA	-0.96
CMPO	-0.957
HHGC	-0.956
IVCP	-0.956
AIB	-0.951
OVLY	-0.951
ACLS	-0.951

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Altamira Therapeutics Correlation - Currency/Commodity

0.27
( neutral )

-0.12
( neutral )

0.00
( neutral )

0.32
( neutral )

0.39
( neutral )

0.37
( neutral )

Altamira Therapeutics Financials

Annual	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-14.80

FY	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-14.80

FY	2022
Revenue:	$305 616
Gross Profit:	$-1.14M (-372.44 %)
EPS:	$-29.13

FY	2021
Revenue:	$63 882.00
Gross Profit:	$-2.18M (-3 407.33 %)
EPS:	$-3.24

Financial Reports:

No articles found.

Altamira Therapeutics

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.